Genetic contributions to the expression of acquired causes of cardiac hypertrophy in non-ischemic sudden cardiac death victims.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 05 2021
Historique:
received: 10 01 2021
accepted: 11 05 2021
entrez: 28 5 2021
pubmed: 29 5 2021
medline: 24 11 2021
Statut: epublish

Résumé

The contribution of genetic variants to non-ischemic sudden cardiac death (SCD) due to acquired myocardial diseases is unclear. We studied whether SCD victims with hypertension/obesity related hypertrophic myocardial disease harbor potentially disease associated gene variants. The Fingesture study has collected data from 5869 autopsy-verified SCD victims in Northern Finland. Among SCD victims, 740 (13%) had hypertension and/or obesity as the most likely explanation for myocardial disease with hypertrophy and fibrosis. We performed next generation sequencing using a panel of 174 cardiac genes for 151 such victims with the best quality of DNA. We used 48 patients with hypertension and hypertrophic heart as controls. Likely pathogenic variants were identified in 15 SCD victims (10%) and variants of uncertain significance (VUS) were observed in additional 43 SCD victims (28%). In controls, likely pathogenic variants were present in two subjects (4%; p = 0.21) and VUSs in 12 subjects (25%; p = 0.64). Among SCD victims, presence of potentially disease-related variants was associated with lower mean BMI and heart weight. Potentially disease related gene variants are common in non-ischemic SCD but further studies are required to determine specific contribution of rare genetic variants to the extent of acquired myocardial diseases leading to SCD.

Identifiants

pubmed: 34045587
doi: 10.1038/s41598-021-90693-7
pii: 10.1038/s41598-021-90693-7
pmc: PMC8159951
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11171

Références

Circulation. 1999 Apr 20;99(15):1978-83
pubmed: 10209001
Circ Cardiovasc Imaging. 2015 Dec;8(12):
pubmed: 26659373
Circulation. 2018 Jun 19;137(25):2716-2726
pubmed: 29915098
J Intern Med. 1999 Feb;245(2):163-74
pubmed: 10081519
Int J Legal Med. 2016 Jan;130(1):91-102
pubmed: 26383259
J Am Coll Cardiol. 2010 Feb 9;55(6):587-97
pubmed: 20152563
Mol Genet Metab. 2003 Sep-Oct;80(1-2):207-15
pubmed: 14567970
J Am Coll Cardiol. 2004 Dec 7;44(11):2192-201
pubmed: 15582318
Eur J Hum Genet. 2020 Jan;28(1):17-22
pubmed: 31534214
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Circulation. 2007 Mar 13;115(10):1244-51
pubmed: 17325244
Circulation. 2006 Nov 14;114(20):2104-12
pubmed: 17060380
Eur J Prev Cardiol. 2018 Mar;25(4):395-401
pubmed: 29319343
Eur Heart J. 2007 Mar;28(5):581-8
pubmed: 17105751
Eur Heart J. 2009 Sep;30(17):2128-36
pubmed: 19525294
Ann Med. 2009;41(2):120-7
pubmed: 18720091
Circulation. 2006 Jun 13;113(23):2697-705
pubmed: 16754800
J Hypertens. 2014 Jan;32(1):16-25
pubmed: 24309485
J Am Coll Cardiol. 1998 Nov;32(5):1454-9
pubmed: 9809962
Heart Rhythm. 2011 Oct;8(10):1570-5
pubmed: 21740887
Circulation. 2006 Oct 3;114(14):1462-7
pubmed: 17000909
JACC Clin Electrophysiol. 2019 Feb;5(2):252-254
pubmed: 30784699
Circulation. 2019 Feb 19;139(8):1012-1021
pubmed: 30779638
Circulation. 2009 Mar 3;119(8):1085-92
pubmed: 19221222
Circulation. 2019 Jul 2;140(1):42-54
pubmed: 31216868
Circulation. 2005 Jul 5;112(1):54-9
pubmed: 15998695
Circulation. 2009 Oct 27;120(17):1657-63
pubmed: 19822806
Br Heart J. 1986 Jun;55(6):575-81
pubmed: 3718796
Nihon Hoigaku Zasshi. 1995 Dec;49(6):458-65
pubmed: 8583689
J Am Coll Cardiol. 2019 Nov 26;74(21):2623-2634
pubmed: 31727422

Auteurs

Lauri Holmström (L)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland. lauri.holmstrom21@gmail.com.

Katri Pylkäs (K)

Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, Oulu, Finland.

Anna Tervasmäki (A)

Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, Oulu, Finland.

Juha Vähätalo (J)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Katja Porvari (K)

Department of Forensic Medicine, Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.

Lasse Pakanen (L)

Department of Forensic Medicine, Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.
Forensic Medicine Unit, National Institute for Health and Welfare (THL), Oulu, Finland.

Kari S Kaikkonen (KS)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Juha S Perkiömäki (JS)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Antti M Kiviniemi (AM)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Risto Kerkelä (R)

Research Unit of Biomedicine, University of Oulu, Oulu, Finland.

Olavi Ukkola (O)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Robert J Myerburg (RJ)

Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA.

Heikki V Huikuri (HV)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Juhani Junttila (J)

Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, 90014, Oulu, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH